UNH
UNH
UnitedHealth Group Incorporated
$419.26
+3.04% 2026-10-20
Health CareS&P 500
UNHSPY
1W
+11.0%
1M
+11.2%
3M
-3.3%
6M
+22.6%
YTD
+29.5%
1Y
+18.1%
Live chart
Loading live chart…
Grades vs sector
Momentum40th pct in sectorC
Momentum
40th pct in sector
12-1 return: +10.3%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth9th pct in sectorD-
Growth
9th pct in sector
Revenue growth (YoY): -0.4%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value57th pct in sectorB-
Value
57th pct in sector
Forward E/P: 5.8% · EBITDA/EV: 7.1%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability50th pct in sectorC+
Profitability
50th pct in sector
Profit margin: +3.5% · Return on equity: +15.8%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15rank 213 of 499 · 12-1 momentum % 15.1
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsStock Market Today: Dow Jumps On U.S.-Iran Hopes; This Warren Buffett Stock Offers Entry (Live Coverage)
Investor's Business Daily · 10h ago
Stock Market Today: Dow Pops, Oil Falls On U.S.-Iran Hopes; Hasbro Rockets, Toys With An Entry (Live Coverage)
Investor's Business Daily · 11h ago
Wall St set for lower open as oil prices jump, earnings in focus
Reuters · 17h ago
Stock Market Today: Dow Wavers As Oil Prices Surge; Netflix, SpaceX Mixed Ahead Of Earnings (Live Coverage)
Investor's Business Daily · 18h ago
Management Raised The Bar For CVS Health Stock; Does The Chart Agree?
Trefis · Oct 19
Key stats
Market cap$376.3B
P/E (trailing)27.0
P/E (forward)18.0
52-week range255.97 – 461.62
Revenue growth (YoY, latest qtr)-0.4%
Dividend yield2.28%
Analyst consensusBuy (25)
Mean price target$477.84 (+14%)
Valuation and fundamentals
Valuation & fundamentals
Bottom line
Leans undervalued
Model read-out from the numbers below, not advice. Score +2 (DCF counts double).
▲DCF (base case)above the price by 46%
•Forward P/E vs sector18.0x vs median 17.6x
•Piotroski F-score6/9
▲Altman Z3.2 (safe)
•Net debt / EBITDA1.9x
•Analyst target+14% (25 analysts)
Discounted cash flow
Bear
$334
-20%
growth 0% · disc. 8.3% · term. 2.0%
Base
$612
+46%
growth 5% · disc. 7.3% · term. 2.5%
Bull
$1,082
+158%
growth 8% · disc. 6.3% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 0% a year for 10 years.
Implied
+0%/yr
FCF, last 3 yrs
-12%/yr
FCF, last 5 yrs
-4%/yr
Revenue, last 3 yrs
+11%/yr
Revenue, last 5 yrs
+12%/yr
Same inputs as the DCF above: trailing free cash flow 23.6B, 7.3% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.61 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
cheaper
sector median 29.9× · 45th pct
27.0×cheaper
Forward P/E
pricier
sector median 17.6× · 51st pct
18.0×pricier
EV / EBITDA
pricier
sector median 15.8× · 53rd pct
16.4×pricier
Price / sales
cheaper
sector median 3.1× · 16th pct
0.8×cheaper
Price / book
pricier
sector median 3.5× · 88th pct
11.4×pricier
FCF yield
cheaper
sector median 4.1% · 79th pct
6.3%cheaper
Forward EPS $23.26 vs trailing $15.55 (+50% expected growth). Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
RPO
$10.7B
as of 2026-06-30
vs a year ago
-10%
YoY
× TTM revenue
0.02×
coverage
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Gross margin
88.6%
Operating margin
4.8%
FCF margin
5.2%
Net margin
3.1%
Return on equity
42.8%
Return on invested capital
22.6%
Net debt / EBITDA
1.9×
Current ratio
0.8×
Interest cover
5.6×
Cash conversion (OCF/NI)
1.9×
Piotroski F-score 6/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved
Altman Z-score 3.2 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$478
+14%
Analysts
25
Buy
Range
$380–$529
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $447.6B | $12.1B | $16.1B |
| 2024 | $400.3B | $14.4B | $20.7B |
| 2023 | $371.6B | $22.4B | $25.7B |
| 2022 | $324.2B | $20.1B | $23.4B |
| 2021 | $287.6B | $17.3B | $19.9B |
| 2020 | $257.1B | $15.4B | $20.1B |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +11.4%.
Earnings
Next report: 2027-01-12 · before open · EPS est 2.26
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-10-13 | 4.14 | 4.69 | +13.3% |
| 2026-07-16 | 4.92 | 6.38 | +29.8% |
| 2026-04-21 | 6.60 | 7.23 | +9.5% |
| 2026-01-27 | 2.11 | 2.11 | +0.2% |
| 2025-10-28 | 2.81 | 2.92 | +4.0% |
| 2025-07-29 | 4.45 | 4.08 | -8.2% |
| 2025-04-17 | 7.29 | 7.20 | -1.3% |
| 2025-01-16 | 6.74 | 6.81 | +1.1% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $112.0B | +0.4% |
| 2026-03-31 | $111.7B | – |
| 2025-12-31 | $113.2B | – |
| 2025-09-30 | $113.2B | – |
| 2025-06-30 | $111.6B | – |
Analyst actions
RBC Capital
PT $498
2026-10-20 · main
Outperform → OutperformPT $498
Bernstein
PT $500
2026-10-16 · main
Outperform → OutperformPT $500
JP Morgan
PT $524
2026-10-16 · main
Overweight → OverweightPT $524
TD Cowen
PT $402
2026-10-15 · reit
Hold → HoldPT $402
Piper Sandler
PT $504
2026-10-14 · main
Overweight → OverweightPT $504
Barclays
PT $440
2026-10-14 · main
Overweight → OverweightPT $440
Recent dividends
2026-09-14: $2.320 · 2026-06-15: $2.320 · 2026-03-09: $2.210 · 2025-12-08: $2.210 · 2025-09-15: $2.210 · 2025-06-16: $2.210 · 2025-03-10: $2.100 · 2024-12-09: $2.100
Insider trades
Conway Patrick Hugh
$455.9K
Chief Executive Officer, Optum · 2026-08-21
SELL$455.9K
Conway Patrick Hugh
$205.0K
Chief Executive Officer, Optum · 2026-08-05
SELL$205.0K
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
Stats refreshed 2026-10-20 17:52:46 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.